Login
$TPST
$0.36 +$0.02 (5.32%) After hours

Company Executives

Officer Age In this role Source
Matthew Angel Also a director
President, Chief Executive Officer and Chair of the Board
45 Not stated
Stephanie Horn-Warnock
Chief Financial Officer, Principal Financial and Accounting Officer, Treasurer, and Corporate Secretary
37 Since 2026
this year

Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.

Directors
5
serving now
Independent
0 of 1
stated in the proxy; 4 not stated
Average tenure
0.0 years
from year joined
CEO also chairs the board
Yes
Matthew Angel
Director Age On board Independent Committees Pay Source
Matthew Angel
45 2026
this year
Not independent None stated Paid as CEO
William Drake Richey
44 2026
this year
Not stated None stated Not stated
John David Yee
63 2026
this year
Not stated None stated Not stated
Nancy Freda-Smith
54 2026
this year
Not stated
Audit · Chair
Not stated
John Frederick
63 2026
this year
Not stated None stated Not stated

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

Erigen LLC
affiliate of Factor, with members Dr. Angel and Lotus Capital BVI Limited
8,268,495 shares of our common stock

Asset Purchase Agreement under which Erigen sold assets to the Company in exchange for shares of common stock

Factor
affiliate of Dr. Angel, provided Funding Commitment under the Asset Purchase Agreement
Up to a maximum of $20.0 million

Factor funding commitment to provide financial support to the Company

With Company Open in proxy
Erigen LLC
affiliate of Factor
Up to $80 million in total upon achievement of certain development milestones

Exclusive license and collaboration agreement assigned to the Company, with milestone and royalty payments

With Novatim Immune Therapeutics Open in proxy
Factor
affiliate of Dr. Angel; Factor Bioscience Limited is a wholly owned subsidiary of Factor
Up to $40 million in total upon achievement of certain development milestones

Amended and restated license and collaboration agreement assigned to the Company, with milestone and royalty payments

With Factor Bioscience Limited Open in proxy
Factor
Amount not stated

Amended and restated master services agreement under which Factor provides services on a fee-for-services basis

With Factor Open in proxy
Factor
Amount not stated
through March 31, 2027

Work Order No. 1 for research and development services through March 31, 2027, with fees waived in part

With Factor Open in proxy
Factor
affiliate of Dr. Angel; Dr. Angel is majority owner and chairman of Factor Bioscience LLC
$5.0 million per year
per year

2026 Master Services Agreement under which Factor provides research and development services for fees

With Tempest Open in proxy
Factor Bioscience Inc.
entity of which Dr. Angel is majority stockholder and Chairman of the Board
$0.5 million
2026

Sale of shares and warrants to Factor in the private placement

With Company Open in proxy
Erigen LLC
affiliate of Factor
Approximately $0.4 million

Company settled Erigen legal fees incurred before the Erigen closing with WSGR, recorded as G&A expense

With Wilson Sonsini Goodrich & Rosati Open in proxy
Andrew Fang
son of Bangxia Yang, the beneficial owner of Lotus, a greater than 5% holder
Up to a maximum aggregate amount of $720,000 per year
per year

Professional Services Agreement under which YQ provides business development and corporate development services at hourly rates

With YQ Advisors Limited Open in proxy

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support